Iron overload: Effects on cellular biochemistry

Clinica Chimica Acta

Volumn 504, Issue , 2020, Pages 180-189

  Sousa, Leilismara ^a   Oliveira, Marina M ^a   Pessôa, Marco Túlio C ^a   Barbosa, Leandro A ^a  

^a FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

Antioxidant system; Iron; Membrane enzymes

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEPCIDIN; IRON REGULATORY FACTOR; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; SUPEROXIDE DISMUTASE; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR 2;

ADIPOSE TISSUE; BONE TISSUE; CARDIOVASCULAR SYSTEM; CELL DAMAGE; CELL FUNCTION; CELL LEVEL; CELL STRUCTURE; EYE TISSUE; FERROPTOSIS; GENITAL SYSTEM; HEMATOPOIETIC TISSUE; HUMAN; IMMUNE SYSTEM; IRON ABSORPTION; IRON HOMEOSTASIS; IRON METABOLISM; IRON OVERLOAD; KIDNEY TISSUE; LIVER TISSUE; MITOCHONDRION; NERVOUS SYSTEM; NONHUMAN; OXIDATIVE STRESS; PANCREAS TISSUE; PRIORITY JOURNAL; REVIEW;

EID: 85076604440     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2019.11.029     Document Type: Review

References (208)

1. Nishito, Y., Kambe, T., Absorption mechanisms of iron, copper, and zinc: an overview. J. Nutr. Sci. Vitaminol. (Tokyo) 64:1 (2018), 1–7.
2. Grotto, H.Z.W., Metabolismo do ferro: uma revisão sobre os principais mecanismos envolvidos em sua homeostase. Revista Brasileira de Hematologia e Hemoterapia 30 (2008), 390–397.
3. Fabiano, A., Brilli, E., Fogli, S., Beconcini, D., Carpi, S., Tarantino, G., et al. Sucrosomial® iron absorption studied by in vitro and ex-vivo models. Eur. J. Pharm. Sci. 111 (2018), 425–431.
4. Barañano, D.E., Wolosker, H., Bae, B.-I., Barrow, R.K., Snyder, S.H., Ferris, C.D., A mammalian iron atpase induced by iron. J. Biol. Chem. 275:20 (2000), 15166–15173.
5. Poss, K.D., Tonegawa, S., Reduced stress defense in heme oxygenase 1-deficient cells. Proc. Natl. Acad. Sci. USA 94:20 (1997), 10925–10930.
6. Poss, K.D., Tonegawa, S., Heme oxygenase 1 is required for mammalian iron reutilization. PNAS 94:20 (1997), 10919–10924.
7. Ferris, C.D., Jaffrey, S.R., Sawa, A., Takahashi, M., Brady, S.D., Barrow, R.K., et al. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat. Cell Biol. 1:3 (1999), 152–157.
8. Smith, S.R., Ghosh, M.C., Ollivierre-Wilson, H., Hang Tong, W., Rouault, T.A., Complete loss of iron regulatory proteins 1 and 2 prevents viability of murine zygotes beyond the blastocyst stage of embryonic development. Blood Cells Mol. Dis. 36:2 (2006), 283–287.
9. Popovic, Z., Templeton, D.M., Interaction of iron regulatory protein-1 (IRP-1) with ATP/ADP maintains a non-IRE-binding state. Biochem. J. 430:2 (2010), 315–324.
10. Melo, Pereira S., Magnetic Reporter Genes for MRI-Based Stem Cell Tracking. 2015, University of Liverpool, Liverpool.
11. Mok, H., Jelinek, J., Pai, S., Cattanach, B.M., Prchal, J.T., Youssoufian, H., et al. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development 131:8 (2004), 1859–1868.
12. Roetto, A., Daraio, F., Alberti, F., Porporato, P., Calı̀, A., De Gobbi, M., et al. Hemochromatosis due to mutations in transferrin receptor 2. Blood Cells Mol. Dis. 29:3 (2002), 465–470.
13. Donovan, A., Roy, C.N., Andrews, N.C., The ins and outs of iron homeostasis. Physiology 21:2 (2006), 115–123.
14. Omotayo, T.I., Akinyemi, G.S., Omololu, P.A., Ajayi, B.O., Akindahunsi, A.A., Rocha, J.B.T., et al. Possible involvement of membrane lipids peroxidation and oxidation of catalytically essential thiols of the cerebral transmembrane sodium pump as component mechanisms of iron-mediated oxidative stress-linked dysfunction of the pump's activity. Redox Biol. 4 (2015), 234–241.
15. Marrogi, A.J., Khan, M.A., van Gijssel, H.E., Welsh, J.A., Rahim, H., Demetris, A.J., et al. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J. Natl. Cancer Inst. 93:21 (2001), 1652–1655.
16. Gürel, A., Armutçu, F., Damatoğlu, Ş., Unalacak, M., Demircan, N., Evaluation of erythrocyte na+, k+ -atpase and superoxide dismutase activities and malondialdehyde level alteration in coal miners. Eur. J. General Med. 1:4 (2004), 22–28.
17. Yakes, F.M., Van Houten, B., Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. 94:2 (1997), 514–519.
18. Rocco-Machado, N., Cosentino-Gomes, D., Meyer-Fernandes, J.R., Modulation of Na+/K+ ATPase activity by hydrogen peroxide generated through Heme in L. amazonensis. PLoS ONE, 10(6), 2015, e0129604.
19. Zarjou, A., Balla, J., Balla, G., Agarwal, A., Iron Metabolism and Oxidative Stress. Miyata, T., Eckardt, K.-U., Nangaku, M., (eds.) Studies on Renal Disorders, 2011, Humana Press, New York City, 205–228.
20. Shahouzehi, B., Nasri, H.R., Masoumi-Ardakani, Y., The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats. ARYA Atheroscler 14:2 (2018), 46–52.
21. Fridovich, I., Competitive inhibition by myoglobin of the reduction of cytochrome c by xanthine oxidase. J. Biol. Chem. 237 (1962), 584–586.
22. Chaudhary, S., Parvez, S., An in vitro approach to assess the neurotoxicity of valproic acid-induced oxidative stress in cerebellum and cerebral cortex of young rats. Neuroscience 225 (2012), 258–268.
23. Sinigaglia, L., Fargion, S., Fracanzani, A.L., Binelli, L., Battafarano, N., Varenna, M., et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J. Rheumatol. 24:9 (1997), 1809–1813.
24. Fracanzani, A.L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A., et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron-related chronic liver disease. Hepatology 33:3 (2001), 647–651.
25. Torti, S.V., Torti, F.M., Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13:5 (2013), 342–355.
26. Wang, H., An, P., Xie, E., Wu, Q., Fang, X., Gao, H., et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology 66:2 (2017), 449–465.
27. Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520:7545 (2015), 57–62.
28. Schneider, L.S., von Schwarzenberg, K., Lehr, T., Ulrich, M., Kubisch-Dohmen, R., Liebl, J., et al. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res. 75:14 (2015), 2863–2874.
29. Racay, P., Kaplán, P., Lehotský, J., Mézesová, V., Rabbit brain endoplasmic reticulum membranes as target for free radicals. Changes in Ca(2+)-transport and protection by stobadine. Biochem. Mol. Biol. Int. 36:3 (1995), 569–577.
30. Kaplán, P., Matejovičová, M., Mézešová, V., Iron-induced inhibition of Na+, K+-ATPase and Na+/Ca2+ exchanger in synaptosomes: protection by the pyridoindole stobadine. Neurochem. Res. 22:12 (1997), 1523–1529.
31. Račay, P., Qteishat, A.W.A., ElKambergy, H.M., Mézešová, V., Lehotský, J., Fe2+-induced inhibition of gerbil forebrain microsomal Ca2+-ATPase: effect of stobadine, glutathione and combination of both antioxidants. Biochim. Biophys. Acta (BBA) – Biomembr. 1370:1 (1998), 119–126.
32. Almeida, A.M., Bertoncini, C.R., Borecký, J., Souza-Pinto, N.C., Vercesi, A.E., Mitochondrial DNA damage associated with lipid peroxidation of the mitochondrial membrane induced by Fe2+-citrate. An. Acad. Bras Cienc. 78:3 (2006), 505–514.
33. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., et al. Ferroptosis: process and function. Cell Death Differ. 23:3 (2016), 369–379.
34. Guzman, J.N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P.T., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:7324 (2010), 696–700.
35. Cabantchik, Z.I., Breuer, W., Zanninelli, G., Cianciulli, P., LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18:2 (2005), 277–287.
36. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C., Cabantchik, Z.I., Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 104:5 (2004), 1504–1510.
37. Oudit, G.Y., Trivieri, M.G., Khaper, N., Liu, P.P., Backx, P.H., Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. 84:5 (2006), 349–364.
38. Brissot, P., Ropert, M., Le Lan, C., Loréal, O., Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta (BBA) – General Subjects 1820:3 (2012), 403–410.
39. Thompson, J.W., Bruick, R.K., Protein degradation and iron homeostasis. BBA 1823:9 (2012), 1484–1490.
40. Cheng, C.-F., Lian, W.-S., Prooxidant mechanisms in iron overload cardiomyopathy. Biomed. Res. Int., 2013, 2013, 8.
41. Anderson, E.R., Shah, Y.M., Iron homeostasis in the liver. Comprehensive Physiol. 3:1 (2013), 315–330.
42. Ivanov, A.V., Bartosch, B., Smirnova, O.A., Isaguliants, M.G., Kochetkov, S.N., HCV and oxidative stress in the liver. Viruses 5:2 (2013), 439–469.
43. Dixon, S.J., Stockwell, B.R., The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10:1 (2014), 9–17.
44. Frey, P.A., Reed, G.H., The ubiquity of iron. ACS Chem. Biol. 7:9 (2012), 1477–1481.
45. Lambeth, J.D., Neish, A.S., Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu. Rev. Pathol. 9 (2014), 119–145.
46. Kell, D.B., Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics., 2, 2009, 2.
47. Bolli, R., Patel, B.S., Zhu, W.X., O'Neill, P.G., Hartley, C.J., Charlat, M.L., et al. The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. Am. J. Physiol.-Heart Circulatory Physiol. 253:6 (1987), H1372–H1380.
48. van der Kraaij, A.M., van Eijk, H.G., Koster, J.F., Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 80:1 (1989), 158–164.
49. Catalá, A., Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 157:1 (2009), 1–11.
50. Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R., Milzani, A., Protein carbonylation in human diseases. Trends Mol. Med. 9:4 (2003), 169–176.
51. Perluigi, M., Coccia, R., Butterfield, D.A., 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid. Redox Signal. 17:11 (2012), 1590–1609.
52. Sousa, L., Garcia, I.J.P., Costa, T.G.F., Silva, L.N.D., Renó, C.O., Oliveira, E.S., et al. Effects of iron overload on the activity of Na, K-ATPase and lipid profile of the human erythrocyte membrane. PLoS ONE, 10(7), 2015, e0132852.
53. Toyokuni, S., Iron-induced carcinogenesis: the role of redox regulation. Free Radic. Biol. Med. 20:4 (1996), 553–566.
54. Eleftheriadis, T., Liakopoulos, V., Antoniadi, G., Stefanidis, I., Which is the best way for estimating transferrin saturation?. Ren Fail. 32:8 (2010), 1022–1023.
55. von Bonsdorff, L., Lindeberg, E., Sahlstedt, L., Lehto, J., Parkkinen, J., Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin. Chem. 48:2 (2002), 307–314.
56. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol. 84:1 (2009), 29–33.
57. Sousa, L., Pessoa, M.T.C., Costa, T.G.F., Cortes, V.F., Santos, H.L., Barbosa, L.A., Iron overload impact on P-ATPases. Ann. Hematol. 97:3 (2018), 377–385.
58. Hollán, S., Membrane fluidity of blood cells. Haematologia (Budap). 27:3 (1996), 109–127.
59. de Lima, Santos H, Lopes, M.L., Maggio, B., Ciancaglini, P., Na, K-ATPase reconstituted in liposomes: effects of lipid composition on hydrolytic activity and enzyme orientation. Colloids Surf. B Biointerfaces 41:4 (2005), 239–248.
60. HeL, Santos, Rigos, C.F., Ciancaglini, P., Kinetics behaviors of Na, K-ATPase: comparison of solubilized and DPPC:DPPE-liposome reconstituted enzyme. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 142:3–4 (2006), 309–316.
61. Gallagher, P.G., Disorders of red cell volume regulation. Curr. Opin. Hematol. 20:3 (2013), 201–207.
62. Ávila, R.A., Silva, M.A.S.C., Peixoto, J.V., Kassouf-Silva, I., Fogaça, R.T.H., Dos Santos, L., Mechanisms involved in the in vitro contractile dysfunction induced by different concentrations of ferrous iron in the rat myocardium. Toxicol. In Vitro. 36 (2016), 38–45.
63. Crichton, R.R., Wilmet, S., Legssyer, R., Ward, R.J., Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J. Inorg. Biochem. 91:1 (2002), 9–18.
64. Jozkowicz, A., Was, H., Dulak, J., Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signal. 9:12 (2007), 2099–2117.
65. Marcantoni, E., Di Francesco, L., Dovizio, M., Bruno, A., Patrignani, P., Novel insights into the vasoprotective role of heme oxygenase-1. Int. J. Hypertens, 2012, 2012, 127910.
66. Zaidi, A., Marden, M.C., Poyart, C., Leclerc, L., Protection by lazaroids of the erythrocyte (Ca2+, Mg2+)-ATPase against iron-induced inhibition. Eur. J. Pharmacol. 290:2 (1995), 133–139.
67. Niggli, V., Adunyah, E.S., Carafoli, E., Acidic phospholipids, unsaturated fatty acids, and limited proteolysis mimic the effect of calmodulin on the purified erythrocyte Ca2+ - ATPase. J. Biol. Chem. 256:16 (1981), 8588–8592.
68. Aulestia, F.J., Alonso, M.T., García-Sancho, J., Differential calcium handling by the cis and trans regions of the Golgi apparatus. Biochem. J. 466:3 (2015), 455–465.
69. Vanoevelen, J., Dode, L., Van Baelen, K., Fairclough, R.J., Missiaen, L., Raeymaekers, L., et al. The secretory pathway Ca2+/Mn2+-ATPase 2 is a golgi-localized pump with high affinity for Ca2+ ions. J. Biol. Chem. 280:24 (2005), 22800–22808.
70. Brini, M., Carafoli, E., Calcium pumps in health and disease. Physiol. Rev. 89:4 (2009), 1341–1378.
71. Stadtman, E.R., Oliver, C.N., Metal-catalyzed oxidation of proteins. Physiological consequences. J. Biol. Chem. 266:4 (1991), 2005–2008.
72. Moore, R.B., Bamberg, A.D., Wilson, L.C., Jenkins, L.D., Mankad, V.N., Ascorbate protects against tert-butyl hydroperoxide inhibition of erythrocyte membrane Ca2+ + Mg2+-ATPase. Arch. Biochem. Biophys. 278:2 (1990), 416–424.
73. Görlach, A., Bertram, K., Hudecova, S., Krizanova, O., Calcium and ROS: a mutual interplay. Redox Biol. 6 (2015), 260–271.
74. Castilho, R.F., Carvalho-Alves, P.C., Vercesi, A.E., Ferreira, S.T., Oxidative damage to sarcoplasmic reticulum Ca2+-pump induced by Fe2+/H2O2/ascorbate is not mediated by lipid peroxidation or thiol oxidation and leads to protein fragmentation. Mol. Cell. Biochem. 159:2 (1996), 105–114.
75. Vasilets, L.A., Schwarz, W., Structure-function relationships of cation binding in the Na+/K+-ATPase. Biochim. Biophys. Acta (BBA) – Rev. Biomembr. 1154:2 (1993), 201–222.
76. +–ATPase inhibition by metal ions and complexes. Hem Ind [Internet] 63 (2009), 499–509.
77. DiGiacomo, J.E., Pane, C.R., Gwiazdowski, S., Mishra, O.P., Delivoria-Papadopoulos, M., Effect of graded hypoxia on brain cell membrane injury in newborn piglets. Biol. Neonate. 61:1 (1992), 25–32.
78. Groenendaal, F., Shadid, M., McGowan, J.E., Mishra, O.P., van Bel, F., Effects of deferoxamine, a chelator of free iron, on Na+, K+-ATPase activity of cortical brain cell membrane during early reperfusion after hypoxia-ischemia in newborn lambs. Pediatr Res. 48:4 (2000), 560–564.
79. Goldshleger, R., Karlish, S.J.D., Fe-catalyzed cleavage of the α subunit of Na/K-ATPase: evidence for conformation-sensitive interactions between cytoplasmic domains. PNAS 94:18 (1997), 9596–9601.
80. Goldshleger, R., Karlish, S.J.D., The energy transduction mechanism of Na, K-ATPase studied with iron-catalyzed oxidative cleavage. J. Biol. Chem. 274:23 (1999), 16213–16221.
81. Karlish, S.J., Investigating the energy transduction mechanism of P-type ATPases with Fe2+-catalyzed oxidative cleavage. Ann. N Y Acad. Sci. 986 (2003), 39–49.
82. Yufu, K., Itoh, T., Edamatsu, R., Mori, A., Hirakawa, M., Effect of hyperbaric oxygenation on the Na+, K(+)-ATPase and membrane fluidity of cerebrocortical membranes after experimental subarachnoid hemorrhage. Neurochem. Res. 18:9 (1993), 1033–1039.
83. Rezin, G.T., Scaini, G., Gonçalves, C.L., Ferreira, G.K., Cardoso, M.R., Ferreira, A.G.K., et al. Evaluation of Na+, K+-ATPase activity in the brain of young rats after acute administration of fenproporex. Revista Brasileira de Psiquiatria 36 (2014), 138–142.
84. Rohn, T.T., Hinds, T.R., Vincenzi, F.F., Inhibition of the Ca pump of intact red blood cells by t-butyl hydroperoxide: importance of glutathione peroxidase. Biochim. Biophys. Acta (BBA) – Biomembr. 1153:1 (1993), 67–76.
85. Silva, L.F., Hoffmann, M.S., Rambo, L.M., Ribeiro, L.R., Lima, F.D., Furian, A.F., et al. The involvement of Na+, K+-ATPase activity and free radical generation in the susceptibility to pentylenetetrazol-induced seizures after experimental traumatic brain injury. J. Neurol. Sci. 308:1–2 (2011), 35–40.
86. Dixon, I.M., Hata, T., Dhalla, N.S., Sarcolemmal Na(+)-K(+)-ATPase activity in congestive heart failure due to myocardial infarction. Am. J. Physiol. – Cell Physiol. 262:3 (1992), C664–C671.
87. Pennell, D.J., Udelson, J.E., Arai, A.E., Bozkurt, B., Cohen, A.R., Galanello, R., et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:3 (2013), 281–308.
88. Murphy, C.J., Oudit, G.Y., Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card Fail. 16:11 (2010), 888–900.
89. Gammella, E., Recalcati, S., Rybinska, I., Buratti, P., Cairo, G., Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxid. Med. Cell. Longevity, 2015, 2015, 10.
90. Chen, Y.-R., Zweier, J.L., Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 114:3 (2014), 524–537.
91. Lakhal-Littleton, S., Wolna, M., Carr, C.A., Miller, J.J.J., Christian, H.C., Ball, V., et al. Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. PNAS 112:10 (2015), 3164–3169.
92. Doroshow, J.H., Locker, G.Y., Myers, C.E., Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest. 65:1 (1980), 128–135.
93. Randell, E.W., Parkes, J.G., Olivieri, N.F., Templeton, D.M., Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem. 269:23 (1994), 16046–16053.
94. Tsushima, R.G., Wickenden, A.D., Bouchard, R.A., Oudit, G.Y., Liu, P.P., Backx, P.H., Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res. 84:11 (1999), 1302–1309.
95. Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9:9 (2003), 1187–1194.
96. N.F. Olivieri, Brittenham GM. Management of the thalassemias. Cold Spring Harbor perspectives in medicine.3(6):a011767.
97. Kremastinos, D.T., Tsiapras, D.P., Tsetsos, G.A., Rentoukas, E.I., Vretou, H.P., Toutouzas, P.K., Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 88:3 (1993), 1127–1135.
98. Olivieri, N.F., Brittenham, G.M., Management of the thalassemias. Cold Spring Harb Perspect Med., 3(6), 2013.
99. Moreau, V.H., Castilho, R.F., Ferreira, S.T., Carvalho-Alves, P.C., Oxidative damage to sarcoplasmic reticulum Ca2+-ATPase AT submicromolar iron concentrations: evidence for metal-catalyzed oxidation. Free Radic. Biol. Med. 25:4–5 (1998), 554–560.
100. Das, S.K., Wang, W., Zhabyeyev, P., Basu, R., McLean, B., Fan, D., et al. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Sci. Rep., 5, 2015, 18132.
101. Aon, M.A., Tocchetti, C.G., Bhatt, N., Paolocci, N., Cortassa, S., Protective mechanisms of mitochondria and heart function in diabetes. Antioxid. Redox Signal. 22:17 (2015), 1563–1586.
102. Li, X., Li, W., Gao, Z., Li, H., Association of cardiac injury with iron-increased oxidative and nitrative modifications of the SERCA2a isoform of sarcoplasmic reticulum Ca2+-ATPase in diabetic rats. Biochimie 127 (2016), 144–152.
103. Gao, X., Qian, M., Campian, J.L., Marshall, J., Zhou, Z., Roberts, A.M., et al. Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radical. Biol. Med. 49:3 (2010), 401–407.
104. Gaenzer, H., Marschang, P., Sturm, W., Gü, Neumayr, Vogel, W., Patsch, J., et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J. Am. Coll. Cardiol. 40:12 (2002), 2189–2194.
105. Drüeke, T., Witko-Sarsat, V., Massy, Z., Descamps-Latscha, B., Guerin, A.P., Marchais, S.J., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:17 (2002), 2212–2217.
106. Reis, K.A., Guz, G., Ozdemir, H., Erten, Y., Atalay, V., Bicik, Z., et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int. Heart J. 46:2 (2005), 255–264.
107. Rostoker, G., Vaziri, N.D., Fishbane, S., Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs 76:7 (2016), 741–757.
108. Pahl, M.V., Vaziri, N.D., Chapter 24 – immune function in chronic kidney disease. Kimmel, P.L., Rosenberg, M.E., (eds.) Chronic Renal Disease, 2015, Academic Press, San Diego, 285–297.
109. Wang, L., Harrington, L., Trebicka, E., Shi, H.N., Kagan, J.C., Hong, C.C., et al. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J. Clin. Investig. 119:11 (2009), 3322–3328.
110. Pagani, A., Nai, A., Corna, G., Bosurgi, L., Rovere-Querini, P., Camaschella, C., et al. Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 118:3 (2011), 736–746.
111. Nairz, M., Haschka, D., Demetz, E., Weiss, G., Iron at the interface of immunity and infection. Front. Pharmacol., 5, 2014, 152-.
112. Kurtoglu, A.U., Kurtoglu, E., Temizkan, A.K., Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. Endokrynol Pol. 63:4 (2012), 260–263.
113. Inati, A., Noureldine, M.A., Mansour, A., Abbas, H.A., Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed. Res. Int., 2015, 2015, 813098-.
114. Cooksey, R.C., Jouihan, H.A., Ajioka, R.S., Hazel, M.W., Jones, D.L., Kushner, J.P., et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145:11 (2004), 5305–5312.
115. Masuda, Y., Ichii, H., Vaziri, N.D., At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death. Am. J. Transl. Res. 6:1 (2013), 64–70.
116. Fernández-Real, J.M., Manco, M., Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2:6 (2014), 513–526.
117. Datz, C., Felder, T.K., Niederseer, D., Aigner, E., Iron homeostasis in the metabolic syndrome. Eur. J. Clin. Invest. 43:2 (2013), 215–224.
118. Wolff, S.P., Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull. 49:3 (1993), 642–652.
119. Shvartsman, M., Kikkeri, R., Shanzer, A., Cabantchik, Z.I., Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am. J. Physiol. Cell Physiol. 293:4 (2007), C1383–C1394.
120. Jiang, R., Manson, J.E., Meigs, J.B., Ma, J., Rifai, N., Hu, F.B., Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:6 (2004), 711–717.
121. Jeney, V., Clinical impact and cellular mechanisms of iron overload-associated bone loss. Front. Pharmacol., 8, 2017, 77-.
122. Messer, J.G., Kilbarger, A.K., Erikson, K.M., Kipp, D.E., Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone 45:5 (2009), 972–979.
123. Mahachoklertwattana, P., Sirikulchayanonta, V., Chuansumrit, A., Karnsombat, P., Choubtum, L., Sriphrapradang, A., et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J. Clin. Endocrinol. Metab. 88:8 (2003), 3966–3972.
124. Rivella, S., The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 26:Suppl 1 (2012), S12–S15.
125. Haidar, R., Mhaidli, H., Musallam, K.M., Taher, A.T., The spine in β-thalassemia syndromes. Spine (Phila Pa 1976) 37:4 (2012), 334–339.
126. Diamond, T., Stiel, D., Posen, S., Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?. Ann. Int. Med. 110:6 (1989), 430–436.
127. Guggenbuhl, P., Deugnier, Y., Boisdet, J.F., Rolland, Y., Perdriger, A., Pawlotsky, Y., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 16:12 (2005), 1809–1814.
128. Angelopoulos, N.G., Goula, A.K., Papanikolaou, G., Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporos Int. 17:1 (2006), 150–155.
129. Balogh, E., Paragh, G., Jeney, V., Influence of iron on bone homeostasis. Pharmaceuticals (Basel), 11(4), 2018.
130. Nankivell, B.J., Boadle, R.A., Harris, D.C., Iron accumulation in human chronic renal disease. Am. J. Kidney Dis. 20:6 (1992), 580–584.
131. Wang, H., Nishiya, K., Ito, H., Hosokawa, T., Hashimoto, K., Moriki, T., Iron deposition in renal biopsy specimens from patients with kidney diseases. Am. J. Kidney Dis. 38:5 (2001), 1038–1044.
132. Naito, Y., Sawada, H., Oboshi, M., Fujii, A., Hirotani, S., Iwasaku, T., et al. Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats. PLoS ONE, 8(10), 2013, e75906.
133. Dominguez, J.H., Liu, Y., Kelly, K.J., Renal iron overload in rats with diabetic nephropathy. Physiol. Rep., 3(12), 2015, e12654.
134. Ward, D.T., Hamilton, K., Burnand, R., Smith, C.P., Tomlinson, D.R., Riccardi, D., Altered expression of iron transport proteins in streptozotocin-induced diabetic rat kidney. Biochim. Biophys. Acta (BBA) – Mol. Basis Disease 1740:1 (2005), 79–84.
135. Quinn, C.T., Johnson, V.L., Kim, H.-Y., Trachtenberg, F., Vogiatzi, M.G., Kwiatkowski, J.L., et al. Renal dysfunction in patients with thalassaemia. Br. J. Haematol. 153:1 (2011), 111–117.
136. Scindia, Y., Dey, P., Thirunagari, A., Liping, H., Rosin, D.L., Floris, M., et al. Hepcidin mitigates renal ischemia-reperfusion injury by modulating systemic iron homeostasis. J. Am. Soc. Nephrol.: JASN 26:11 (2015), 2800–2814.
137. Sikorska, K., Stalke, P., Romanowski, T., Rzepko, R., Bielawski, K.P., Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. Hepatobiliary Pancreatic Diseases Int. 12:4 (2013), 377–384.
138. Pietrangelo, A., Iron and the liver. Liver Int. 36:S1 (2016), 116–123.
139. Camaschella, C., Nai, A., Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br. J. Haematol. 172:4 (2016), 512–523.
140. Moukhadder, H.M., Halawi, R., Cappellini, M.D., Taher, A.T., Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer 123:5 (2017), 751–758.
141. Milic, S., Mikolasevic, I., Orlic, L., Devcic, E., Starcevic-Cizmarevic, N., Stimac, D., et al. The role of iron and iron overload in chronic liver disease. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res. 22 (2016), 2144–2151.
142. Osborne, N.J., Gurrin, L.C., Allen, K.J., Constantine, C.C., Delatycki, M.B., McLaren, C.E., et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatol. (Baltimore, MD) 51:4 (2010), 1311–1318.
143. Borgna-Pignatti, C., Vergine, G., Lombardo, T., Cappellini, M.D., Cianciulli, P., Maggio, A., et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol. 124:1 (2004), 114–117.
144. Silva-Gomes, S., Santos, A.G., Caldas, C., Silva, C.M., Neves, J.V., Lopes, J., et al. Transcription factor NRF2 protects mice against dietary iron-induced liver injury by preventing hepatocytic cell death. J. Hepatol. 60:2 (2014), 354–361.
145. Gabrielsen, J.S., Gao, Y., Simcox, J.A., Huang, J., Thorup, D., Jones, D., et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Investig. 122:10 (2012), 3529–3540.
146. Valenti, L., Fracanzani, A.L., Dongiovanni, P., Rovida, S., Rametta, R., Fatta, E., et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J. Gastroenterol. 20:11 (2014), 3002–3010.
147. Chai, X., Li, D., Cao, X., Zhang, Y., Mu, J., Lu, W., et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. Sci. Rep., 5, 2015, 10181.
148. Taoka, K., Kumano, K., Nakamura, F., Hosoi, M., Goyama, S., Imai, Y., et al. The effect of iron overload and chelation on erythroid differentiation. Int. J. Hematol. 95:2 (2012), 149–159.
149. Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A.X., Gerlach, M., Riederer, P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76:6 (2001), 1766–1773.
150. Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. PNAS 101:26 (2004), 9843–9848.
151. Hare, D.J., Arora, M., Jenkins, N.L., Finkelstein, D.I., Doble, P.A., Bush, A.I., Is early-life iron exposure critical in neurodegeneration?. Nat. Rev. Neurol. 11:9 (2015), 536–544.
152. Schröder, N., Figueiredo, L.S., de Lima, M.N., Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies. J. Alzheimers Dis. 34:4 (2013), 797–812.
153. Greenough, M.A., Ramírez Munoz, A., Bush, A.I., Opazo, C.M., Metallo-pathways to Alzheimer's disease: lessons from genetic disorders of copper trafficking. Metallomics 8:9 (2016), 831–839.
154. Wong, R.W., Richa, D.C., Hahn, P., Green, W.R., Dunaief, J.L., Iron toxicity as a potential factor in amd. Retina 27:8 (2007), 997–1003.
155. Ward, R.J., Zucca, F.A., Duyn, J.H., Crichton, R.R., Zecca, L., The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13:10 (2014), 1045–1060.
156. Singh, N., Haldar, S., Tripathi, A.K., Horback, K., Wong, J., Sharma, D., et al. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid. Redox Signal. 20:8 (2014), 1324–1363.
157. Poujois, A., Devedjian, J.C., Moreau, C., Devos, D., Chaine, P., Woimant, F., et al. Bioavailable trace metals in neurological diseases. Curr. Treat Options Neurol., 18(10), 2016, 46.
158. Rouault, T.A., Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14:8 (2013), 551–564.
159. Hentze, M.W., Muckenthaler, M.U., Galy, B., Camaschella, C., Two to tango: regulation of mammalian iron metabolism. Cell 142:1 (2010), 24–38.
160. Wang, J., Pantopoulos, K., Regulation of cellular iron metabolism. Biochem. J. 434:3 (2011), 365–381.
161. Conde, J.R., Streit, W.J., Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65:3 (2006), 199–203.
162. Farrall, A.J., Wardlaw, J.M., Blood–brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol. Aging 30:3 (2009), 337–352.
163. Williams, R., Buchheit, C.L., Berman, N.E.J., LeVine, S.M., Pathogenic implications of iron accumulation in multiple sclerosis. J. Neurochem. 120:1 (2012), 7–25.
164. Xu, J., Jia, Z., Knutson, M.D., Leeuwenburgh, C., Impaired iron status in aging research. Int. J. Mol. Sci. 13:2 (2012), 2368–2386.
165. Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N.P., Arredondo, M., et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 126:4 (2013), 541–549.
166. Castellani, R.J., Siedlak, S.L., Perry, G., Smith, M.A., Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100:2 (2000), 111–114.
167. Faucheux, B.A., Martin, M.-E., Beaumont, C., Hauw, J.-J., Agid, Y., Hirsch, E.C., Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86:5 (2003), 1142–1148.
168. Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben-Shachar, D., et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-Ray microanalysis. J. Neurochem. 59:3 (1992), 1168–1171.
169. Good, P.F., Olanow, C.W., Perl, D.P., Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593:2 (1992), 343–346.
170. Lei, P., Ayton, S., Finkelstein, D.I., Spoerri, L., Ciccotosto, G.D., Wright, D.K., et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18:2 (2012), 291–295.
171. Duce, J.A., Tsatsanis, A., Cater, M.A., James, S.A., Robb, E., Wikhe, K., et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142:6 (2010), 857–867.
172. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boonplueang, R., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37:6 (2003), 899–909.
173. Schipper, H., Kotake, Y., Janzen, E., Catechol oxidation by peroxidase-positive astrocytes in primary culture: an electron spin resonance study. J. Neurosci. 11:7 (1991), 2170–2176.
174. Sulzer, D., Zecca, L., Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 1:3 (2000), 181–195.
175. Paris, I., Martinez-Alvarado, P., Cárdenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., et al. Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem. Res. Toxicol. 18:3 (2005), 415–419.
176. S. Dev, J.L. Babitt, Overview of iron metabolism in health and disease. Hemodialysis international International Symposium on Home Hemodialysis, 2017, 21 (Suppl 1), S6–S20.
177. He, X., Hahn, P., Iacovelli, J., Wong, R., King, C., Bhisitkul, R., et al. Iron homeostasis and toxicity in retinal degeneration. Prog. Retin Eye Res. 26:6 (2007), 649–673.
178. Chaudhary, K., Promsote, W., Ananth, S., Veeranan-Karmegam, R., Tawfik, A., Arjunan, P., et al. Iron overload accelerates the progression of diabetic retinopathy in association with increased retinal renin expression. Sci. Rep., 8(1), 2018, 3025.
179. Cussimanio, B.L., Booth, A.A., Todd, P., Hudson, B.G., Khalifah, R.G., Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation. Biophys. Chem. 105:2–3 (2003), 743–755.
180. Gnana-Prakasam, J.P., Thangaraju, M., Liu, K., Ha, Y., Martin, P.M., Smith, S.B., et al. Absence of iron-regulatory protein Hfe results in hyperproliferation of retinal pigment epithelium: role of cystine/glutamate exchanger. Biochem. J. 424:2 (2009), 243–252.
181. Song, D., Kanu, L.N., Li, Y., Kelly, K.L., Bhuyan, R.K., Aleman, T., et al. AMD-like retinopathy associated with intravenous iron. Exp. Eye Res. 151 (2016), 122–133.
182. Dawczynski, J., Blum, M., Winnefeld, K., Strobel, J., Increased content of zinc and iron in human cataractous lenses. Biol. Trace Elem. Res. 90:1–3 (2002), 15–23.
183. Farkas, R.H., Chowers, I., Hackam, A.S., Kageyama, M., Nickells, R.W., Otteson, D.C., et al. Increased expression of iron-regulating genes in monkey and human glaucoma. Invest. Ophthalmol. Vis. Sci. 45:5 (2004), 1410–1417.
184. Vercellini, P., Crosignani, P., Somigliana, E., Viganò, P., Buggio, L., Bolis, G., et al. The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum. Reprod. 26:9 (2011), 2262–2273.
185. Yamaguchi, K., Mandai, M., Toyokuni, S., Hamanishi, J., Higuchi, T., Takakura, K., et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin. Cancer Res. 14:1 (2008), 32–40.
186. Seidman, J.D., The presence of mucosal iron in the fallopian tube supports the “incessant menstruation hypothesis” for ovarian carcinoma. Int. J. Gynecol. Pathol. 32:5 (2013), 454–458.
187. Salazar, J.J., Van Houten, B., Preferential mitochondrial DNA injury caused by glucose oxidase as a steady generator of hydrogen peroxide in human fibroblasts. Mutation Res./DNA Repair 385:2 (1997), 139–149.
188. Melis, J.P.M., van Steeg, H., Luijten, M., Oxidative DNA damage and nucleotide excision repair. Antioxid. Redox Signal. 18:18 (2013), 2409–2419.
189. Shvartsman, M., Fibach, E., Cabantchik, Z.I., Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Biochem. J. 429:1 (2010), 185–193.
190. Esposito, L.A., Melov, S., Panov, A., Cottrell, B.A., Wallace, D.C., Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl. Acad. Sci. USA 96:9 (1999), 4820–4825.
191. Fortes, G.B., Alves, L.S., de Oliveira, R., Dutra, F.F., Rodrigues, D., Fernandez, P.L., et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood 119:10 (2012), 2368–2375.
192. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:5 (2012), 1060–1072.
193. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156:1–2 (2014), 317–331.
194. Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A.J., Yang, W.S., Fridman, D.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447:7146 (2007), 864–868.
195. Yang, W.S., Stockwell, B.R., Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15:3 (2008), 234–245.
196. Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63:1 (2016), 173–184.
197. Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64:2 (2016), 488–500.
198. Gao, M., Monian, P., Quadri, N., Ramasamy, R., Jiang, X., Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell. 59:2 (2015), 298–308.
199. Kwon, M.Y., Park, E., Lee, S.J., Chung, S.W., Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6:27 (2015), 24393–24403.
200. Abeysinghe, R.D., Roberts, P.J., Cooper, C.E., MacLean, K.H., Hider, R.C., Porter, J.B., The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J. Biol. Chem. 271:14 (1996), 7965–7972.
201. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136:12 (2014), 4551–4556.
202. Dolma, S., Lessnick, S.L., Hahn, W.C., Stockwell, B.R., Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3:3 (2003), 285–296.
203. Shimada, K., Hayano, M., Pagano, N.C., Stockwell, B.R., Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem. Biol. 23:2 (2016), 225–235.
204. Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S.R., Dewitz, C., De Zen, F., et al. Synchronized renal tubular cell death involves ferroptosis. PNAS 111:47 (2014), 16836–16841.
205. Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26:3 (2016), 165–176.
206. Dixon, S.J., Ferroptosis: bug or feature?. Immunol. Rev. 277:1 (2017), 150–157.
207. Ueda, S., Nakamura, H., Masutani, H., Sasada, T., Yonehara, S., Takabayashi, A., et al. Redox Regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and Cytochrome c. J. Immunol., 161(12), 1998, 6689.
208. Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol., 12(1), 2019, 34.